糖尿病合并复杂冠脉病变血运重建后十年全因死亡:SYNTAXES 研究
SYNTAXES 研究评估了 SYNTAX 试验中 1800 例三支病变和/或左主干病变患者随机接受 PCI 或 CABG 后的 10 年生存率。在糖尿病患者中,10 年全因死亡在 PCI 与 CABG 间无显著差异,绝对差异 1.9%(36.4% vs 34.5%,P=0.551);胰岛素治疗患者中 PCI 死亡数值更高但未达统计学显著。
要点
- 糖尿病患者 PCI 与 CABG 10 年全因死亡无显著差异(36.4% vs 34.5%,P=0.551)。
- 胰岛素治疗患者 PCI 10 年死亡数值更高(47.9% vs 39.6%,P=0.227),需进一步研究。
- 非糖尿病患者同样未见 PCI 与 CABG 10 年全因死亡显著差异。
核心结论
- 在三支病变和/或左主干病变患者中,PCI 与 CABG 对 10 年全因死亡的治疗效应在有无糖尿病者中相似。
- 胰岛素治疗糖尿病患者中 CABG 可能存在生存获益,但需专门试验进一步验证。
研究设计与样本
- SYNTAXES 研究为 SYNTAX 试验的延长随访,评估 up to 10 年生存。
- 共纳入 1800 例三支病变和/或左主干病变患者,随机接受 PCI 或 CABG。
- 糖尿病患者 452 例,胰岛素治疗患者 182 例。
主要发现
- 糖尿病患者 5 年死亡:PCI 19.6% vs CABG 13.3%(HR 1.53,95%CI 0.96–2.43,P=0.075)。
- 糖尿病患者 5–10 年死亡:PCI 20.8% vs CABG 24.4%(HR 0.82,95%CI 0.52–1.27,P=0.366)。
- 糖尿病患者 10 年全因死亡:PCI 36.4% vs CABG 34.5%,绝对差异 1.9%(95%CI -7.6%–11.1%,P=0.551)。
- 胰岛素治疗患者 10 年全因死亡:PCI 47.9% vs CABG 39.6%,差异 8.2%(95%CI -6.5%–22.5%,P=0.227)。
临床怎么用
- 对糖尿病合并三支病变和/或左主干病变患者,PCI 与 CABG 的 10 年全因死亡风险总体相似。
- 胰岛素治疗糖尿病患者选择血运重建策略时,可考虑 CABG 潜在的生存获益,但需个体化决策。
局限性
- 胰岛素治疗亚组样本量较小(n=182),结果需专门试验进一步验证。
- 原文指出血运重建策略与糖尿病患者的极长期缺血及安全性结局的关联需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this article was to compare rates of all-cause death at 10 years following coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in patients with or without diabetes. METHODS AND RESULTS: The SYNTAXES study evaluated up to 10-year survival of 1800 patients with three-vessel disease (3VD) and/or left main coronary artery disease (LMCAD) randomized to receive either PCI or CABG in the SYNTAX trial. Ten-year all-cause death according to diabetic status and revascularization strategy was examined. In diabetics (n = 452), the risk of mortality was numerically higher with PCI compared with CABG at 5 years [19.6% vs. 13.3%, hazard ratio (HR): 1.53, 95% confidence interval (CI): 0.96, 2.43, P = 0.075], with the opposite seen between 5 and 10 years (PCI vs. CABG: 20.8% vs. 24.4%, HR: 0.82, 95% CI: 0.52, 1.27, P = 0.366). Irrespective of diabetic status, there was no significant difference in all-cause death at 10 years between patients receiving PCI or CABG, the absolute treatment difference was 1.9% in diabetics (PCI vs. CABG: 36.4% vs. 34.5%, difference: 1.9%, 95% CI: -7.6%, 11.1%, P = 0.551). Among insulin-treated patients (n = 182), all-cause death at 10 years was numerically higher with PCI (47.9% vs. 39.6%, difference: 8.2%, 95% CI: -6.5%, 22.5%, P = 0.227). CONCLUSIONS: The treatment effects of PCI vs. CABG on all-cause death at 10 years in patients with 3VD and/or LMCAD were similar irrespective of the presence of diabetes. There may, however, be a survival benefit with CABG in patients with insulin-treated diabetes. The association between revascularization strategy and very long-term ischaemic and safety outcomes for patients with diabetes needs further investigation in dedicated trials. TRIAL REGISTRATION: SYNTAX: ClinicalTrials.gov reference: NCT00114972 and SYNTAX Extended Survival: ClinicalTrials.gov reference: NCT03417050.
引用
- Wang R, Serruys PW, Gao C, et al. Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. Eur Heart J. 2021. PMID: 34405232. doi:10.1093/eurheartj/ehab441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。